116 filings
Page 3 of 6
8-K
wrpxnstqqj3d
16 Oct 20
Entry into a Material Definitive Agreement
8:58am
8-K
chb0s1udi0uat
30 Jul 20
MacroGenics Provides Update on Corporate Progress and Second Quarter 2020 Financial Results
9:59pm
8-K
2a5z58fko0q km6igcub
19 Jun 20
Other Events
5:01pm
8-K
hxcnusr up
18 Jun 20
MacroGenics Appoints Dr. Stephen Eck As Chief Medical Officer
8:16am
8-K
qdz9ckpuo65ir
29 May 20
Other Events
8:33am
8-K
olgm9n
14 May 20
Submission of Matters to a Vote of Security Holders
5:00pm
8-K
1k9 iupq1d4jbs
13 May 20
MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting
5:12pm
8-K
wycdy
5 May 20
MacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial Results
4:05pm
8-K
dtxcjoj2 ore1skblk
28 Apr 20
MacroGenics to Host its Annual Meeting of Stockholders in Virtual Format
4:04pm
8-K
e5jyaxep
4 Mar 20
MacroGenics Announces Departure of Chief Medical Officer
5:08pm
8-K
lox1lg0tfxb
25 Feb 20
MacroGenics Provides Update on Corporate Progress and 2019 Financial Results
4:07pm
8-K
jgte42gz21jwmcp4v4u3
5 Feb 20
Departure of Directors or Certain Officers
4:30pm
8-K
xom7rphu74v20xg nynn
10 Jan 20
Results of Operations and Financial Condition
12:00am
8-K
cpgl iawd5
6 Nov 19
MacroGenics Provides Update on Corporate Progress and Third Quarter 2019 Financial Results
4:10pm
8-K
c5wma6e zm3q2k3xl
22 Oct 19
Other Events
4:34pm
8-K
n6zyzcirej gf1r
31 Jul 19
MacroGenics Provides Update on Corporate Progress and Second Quarter 2019 Financial Results
4:06pm
8-K
j7jexyxufxsl25pkzgz
17 Jul 19
MacroGenics Provides Update on Flotetuzumab Program in Acute Myeloid Leukemia
4:17pm
8-K
4ii9qhs0b433n102w
21 May 19
Submission of Matters to a Vote of Security Holders
12:00am
8-K
96h4ycc1
1 May 19
MacroGenics Provides Update on Corporate Progress and First Quarter 2019 Financial Results
4:08pm
8-K
cuq fjinscs
26 Feb 19
MacroGenics Provides Update on Corporate Progress and 2018 Financial Results
4:05pm